{"nct_id":"NCT03439280","title":"A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)","status":"COMPLETED","status_verified_date":"2023-01","start_date":"2018-04-20","start_date_type":"ACTUAL","primary_completion_date":"2022-01-28","primary_completion_date_type":"ACTUAL","completion_date":"2022-01-28","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["TAK"]}